RxDoctor Payments Data

Aijaz Ahmed, MD

Gastroenterology · Stanford, CANPI 1447351747

Payments from drug & device makers

$339,448in general payments, 2019–2025

Across 148 payments — averaging $2293.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$259K
  • Intercept Pharma Europe Ltd.$58K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$10K
  • Merck$8K
  • Novo Nordisk$3K
  • Siemens Medical Solutions USA, Inc.$1K
  • plus $701 from 3 others

What the payments were for

  • Consulting fees$10,43842%
  • Speaking & faculty fees$12,66350%
  • Travel & lodging$1,4616%
  • Food & beverage$5352%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$339,448 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$117,281
Medicare patients
480
Services billed
797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide123$177,869
XifaxanRifaximin20$71,678
Tacrolimus211$38,185
Entecavir83$28,661
Ursodiol150$26,059
Mycophenolate Mofetil89$15,120
EliquisApixaban23$13,415
Sirolimus19$11,873
Azathioprine37$2,225
Fluconazole14$1,291
Tenofovir Disoproxil Fumarate29$1,252
Fludrocortisone Acetate40$1,140
Colchicine12$744
PrevaliteCholestyramine12$638
Omeprazole25$609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$10,094$71,67820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →